CareDx Preliminary Q4 Revenues Up 63 Percent, Beat Estimates

Jan 11, 2021

|

NEW YORK – CareDx said on Monday that it expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.

On average, analysts are expecting Q4 revenues of $53.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

CareDx Preliminary Q4 Revenues Up 63 Percent, Beat Estimates

To read the full story....

Breaking News

Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

What's Popular?

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Roche Renews Agreement to Distribute Sysmex Hematology Products

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

Sponsorships